» Articles » PMID: 20502614

Platelet Transfusions: Trigger, Dose, Benefits, and Risks

Overview
Journal F1000 Med Rep
Specialty General Medicine
Date 2010 May 27
PMID 20502614
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Over the last half century, platelet transfusion has been an effective therapy for the prevention and treatment of bleeding, particularly in patients with hematologic malignancies. Recent randomized trials have demonstrated that current practices may be suboptimal in a number of ways. The rationale for parsimony in the use of this powerful therapy includes previously described severe and fatal adverse outcomes (including refractoriness, hemolysis from ABO-mismatched transfusions, acute lung injury, and bacterial sepsis), newly described serious potential risks (including thrombosis and earlier leukemic recurrence), difficulty in maintaining adequate supplies of platelets, the need to place volunteer donors on cell separators to provide the product, and cost. Recent findings demonstrate that the platelet count threshold for prophylactic transfusion can be as low as 10,000/µL, and a therapeutic rather than a prophylactic strategy of transfusion for bleeding manifestations only may be equally safe for most patients. Another recently completed study suggests that very low doses of platelet transfusions (the equivalent of half a unit of apheresis platelets or two to three units of whole blood-derived platelets) are as effective at preventing bleeding as much higher doses. One question for which there are no randomized trial data is at what threshold prophylactic platelet transfusion should be given before invasive procedures or major surgery. The typically recommended threshold of 50,000/µL is based only on expert opinion, and substantial observational data indicate that this threshold leads to many transfusions that are likely unnecessary and therefore represent risk with little or no additional benefit.

Citing Articles

Visualization of Critical Limits and Critical Values Facilitates Interpretation.

Shah A, Dohner J, Cheng K, Garcia M, Kost G Diagnostics (Basel). 2025; 15(5).

PMID: 40075851 PMC: 11899349. DOI: 10.3390/diagnostics15050604.


Accelerates Megakaryopoiesis and Thrombopoiesis via Activating PI3K/Akt and MEK/ERK Signaling Pathways.

Yang X, Wang L, Zeng J, Wu A, Qin M, Wen M Pharmaceuticals (Basel). 2022; 15(10).

PMID: 36297316 PMC: 9607024. DOI: 10.3390/ph15101204.


Efficacy of eltrombopag in thrombocytopenia after hematopoietic stem celltransplantation.

Karatas A, Goker H, Demiroglu H, Malkan U, Velet M, Cinar O Turk J Med Sci. 2022; 52(2):413-419.

PMID: 36161632 PMC: 10381231. DOI: 10.55730/1300-0144.5328.


Avatrombopag ethnic sensitivity analysis in chronic liver disease and thrombocytopenia patients: individual-level pooled analysis.

Lu J, Jamieson B, Hui A Therap Adv Gastroenterol. 2022; 15:17562848221105976.

PMID: 35795378 PMC: 9252017. DOI: 10.1177/17562848221105976.


Bleeding disorders in implant dentistry: a narrative review and a treatment guide.

Romer P, Heimes D, Pabst A, Becker P, Thiem D, Kammerer P Int J Implant Dent. 2022; 8(1):20.

PMID: 35429255 PMC: 9013394. DOI: 10.1186/s40729-022-00418-2.


References
1.
Sapatnekar S, Sharma G, Downes K, Wiersma S, McGrath C, Yomtovian R . Acute hemolytic transfusion reaction in a pediatric patient following transfusion of apheresis platelets. J Clin Apher. 2005; 20(4):225-9. DOI: 10.1002/jca.20072. View

2.
Spiess B, Royston D, Levy J, Fitch J, Dietrich W, Body S . Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes. Transfusion. 2004; 44(8):1143-8. DOI: 10.1111/j.1537-2995.2004.03322.x. View

3.
Josephson C, Mullis N, Van Demark C, Hillyer C . Significant numbers of apheresis-derived group O platelet units have "high-titer" anti-A/A,B: implications for transfusion policy. Transfusion. 2004; 44(6):805-8. DOI: 10.1111/j.1537-2995.2004.03290.x. View

4.
Lawrence J, Yomtovian R, Hammons T, Masarik S, Chongkolwatana V, Creger R . Lowering the prophylactic platelet transfusion threshold: a prospective analysis. Leuk Lymphoma. 2001; 41(1-2):67-76. DOI: 10.3109/10428190109057955. View

5.
Brand A, Novotny V, Tomson B . Platelet transfusion therapy: from 1973 to 2005. Hum Immunol. 2006; 67(6):413-8. DOI: 10.1016/j.humimm.2006.03.005. View